Compare ELVN & DAVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ELVN | DAVE |
|---|---|---|
| Founded | 2016 | 2017 |
| Country | United States | United States |
| Employees | N/A | 280 |
| Industry | Biotechnology: Pharmaceutical Preparations | Retail: Computer Software & Peripheral Equipment |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 3.1B |
| IPO Year | 2020 | N/A |
| Metric | ELVN | DAVE |
|---|---|---|
| Price | $39.56 | $277.20 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 8 |
| Target Price | $43.40 | ★ $312.75 |
| AVG Volume (30 Days) | ★ 563.9K | 410.1K |
| Earning Date | 05-11-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 3.17 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $26.28 |
| Revenue Next Year | N/A | $17.38 |
| P/E Ratio | ★ N/A | $17.85 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $14.79 | $152.21 |
| 52 Week High | $48.53 | $287.69 |
| Indicator | ELVN | DAVE |
|---|---|---|
| Relative Strength Index (RSI) | 43.32 | 64.20 |
| Support Level | $38.58 | $163.21 |
| Resistance Level | $40.62 | $282.07 |
| Average True Range (ATR) | 2.24 | 16.05 |
| MACD | -0.29 | 1.76 |
| Stochastic Oscillator | 12.81 | 84.32 |
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. The product candidates of the company include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.
Dave Inc is a financial services company. It is engaged in offering banking app that offers its customers banking, financial insights, overdraft protection, building credit, short-term liquidity, fee-free banking, and financial management tools, and finding side gigs.